Comparative Pharmacology
Head-to-head clinical analysis: CORTEF ACETATE versus LEXETTE.
Peer-Reviewed Evidence
Head-to-head clinical analysis: CORTEF ACETATE versus LEXETTE.
CORTEF ACETATE vs LEXETTE
Comparing the clinical profiles, pharmacokinetic behaviors, and safety indices of these two therapeutic agents.
Corticosteroid with anti-inflammatory and immunosuppressant activity; binds to glucocorticoid receptors, modulating gene expression and inhibiting phospholipase A2, thereby reducing prostaglandin and leukotriene synthesis.
LEXETTE (halobetasol propionate) is a corticosteroid that exerts anti-inflammatory, antipruritic, and vasoconstrictive effects. The primary mechanism involves binding to glucocorticoid receptors, which modulates gene transcription to inhibit phospholipase A2, reduce prostaglandin and leukotriene synthesis, and suppress cytokine release.
Adult: 5-60 mg orally every 6-12 hours (hydrocortisone base equivalent), or 10-240 mg IV/IM every 12 hours (as hydrocortisone sodium succinate). Dose depends on severity and condition.
Apply to affected areas once daily for up to 2 weeks. Use no more than 60 g per week.
None Documented
None Documented
Plasma terminal half-life is approximately 1.5-2 hours. However, biologic half-life (duration of adrenal suppression) is 18-36 hours due to intracellular receptor binding.
Terminal elimination half-life is 12-15 hours, supporting twice-daily dosing in clinical practice.
Primarily renal as inactive metabolites; less than 5% unchanged. Biliary/fecal elimination is minimal (<2%).
Primarily renal excretion of unchanged drug (approximately 70%), with 30% metabolized hepatically via CYP3A4 and excreted as inactive metabolites in urine and feces.
Category C
Category C
Topical Corticosteroid
Topical Corticosteroid